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Results.— One hundred and seventy-three paired measurements
were compared. The mean CO (SD) was 2.5(1.4) l/min with TEE-
CO and 2.3(1.4) l/min with PRAM-CO. The mean bias was 0.2 l/min
with agreements limits —2.4 and 2.8 l/min. Pearson’s correlation
was 0.29 giving a percentage error of 108%. In the group with median
BSA < 1.10 m2 (n = 26, 131 measures), mean CO was 1.9 (0.7) l/min
with TEE-CO and 1.8(0.6) l/min with PRAM-CO. The mean bias was
0.03 l/min with agreements limits —1.06 and 1.13 l/min. Pearson’s
correlation was 0.64 giving a percentage error of 60%.
Conclusions.— Differences between PRAM and TEE were signiﬁcant
at all ages and BSA. These results do not support the use of the
Mostcare® monitor to evaluate CO in the setting of pediatric cardiac
surgery.
http://dx.doi.org/10.1016/j.acvd.2013.06.039
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Introduction.— Heart transplantation is the gold standard therapy
for pediatric end-stage heart failure. Sometimes, the waiting time
for a transplant may be long and a mechanical support is required
despite the use of conventional inotropic drugs. Levosimendan was
proved to be safe and efﬁcient for the treatment of postoperative
low cardiac output syndrome in children.
Aims.— To evaluate the effects of levosimendan in children who are
waiting for heart transplantation.
Patients and methods.— In this single-center retrospective study,
all the pediatric patients (under 18 years) in end-stage heart fail-
ure and with criteria for mechanical support, were included. All
the patients were on the waiting list for heart transplantation. Each
patient received at least one 24-hour infusion of levosimendan until
either heart transplantation or mechanical support initiation. Clini-
cal, biological and echocardiographic data were analyzed according
to the infusions of levosimendan.
Results.— A total of six patients were included over a period of
24 months. The median age was 2 years (2 months—15 years). A
total of 82 infusions were performed. Levosimendan had a positive
effect on enteral feeding. The median BNP level decreased signif-
icantly between day 0 and day 2 (2443 ng/L [1458—3819] versus
1358 ng/L [1025—2534], P = 0.003). While only a trend was noted in
the improvement of the left ventricular ejection fraction (P = 0.054
by the Simpson’s method and P = 0.068 by the Teicholz method), the
subaortic velocity time integral was signiﬁcantly improved between
day 0 and day 8 (12.8 cm/s [10—14.5] versus 15.3 cm/s [14.3—16.9],
P = 0.041). Even if the efﬁcacy of levosimendan seemed to pro-
gressively decrease over the time, the use of this drug allowed an
average lifetime without mechanical support of 177 days. During
this study, no adverse events have been reported, or attributed, to
the use of levosimendan.
Conclusion.— Levosimendan improves hemodynamics in children
in end-stage heart failure, allowing several months of life with-
out mechanical support. This study argues for a systematic use
of levosimendan, in addition to the usual inotropic drugs, in this
context. Levels of BNP, quality of enteral feeding and echocar-
diographic parameters may help to determine the best timing for
infusions.
http://dx.doi.org/10.1016/j.acvd.2013.06.040
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Introduction.— Rejection following cardiac transplant remains
an important cause of morbidity and mortality as well as the
complications of the immunosuppressive therapy. Thus, surveil-
lance of paediatric heart transplant patients is crucial to prevent
these risks or, at least, to allow an early treatment. However, only
few international guidelines have been established concerning the
modalities of this monitoring.
Aims.— To collect and to compare the different practices of paedi-
atric heart transplant surveillance in France.
Patients and methods.— It was a descriptive multicenter study. Each
French paediatric cardiologic centres was contacted by e-mail to
complete an electronic questionnaire.
Results.— Eight centres were involved in the surveillance (includ-
ing seven centres performing paediatric heart transplantation) of
these patients. The average number of followed patients was 16.1
(2—50) per centre. The average number of involved physicians was
3.7 (1—8) including 38% of paediatric cardiologists. Only two cen-
tres had a devoted nurse for this activity. Echocardiography was
considered to be reliable for the early detection of transplant
rejection by 57% of centres. Isovolumic relaxation time was always
collected. Whereas TM measurements were frequently analyzed,
other Doppler measurements were inconsistently reported. Myocar-
dial strain analysis (using speckle tracking method) was almost never
performed (14%). Coronarography was systematically performed in
43%, coronary CT angiogram in 28% and cardiac MRI in 14%. For
patients aged above 1 year, cardiac biopsies were systematically
performed in 86%. The prevention of the transplant coronary artery
disease was conducted using pravastatin in 86%, aspirin in 28% and
clopidogrel in 14%.
Conclusion.— The French practices for the monitoring of paediatric
heart transplant patients are heterogeneous due to the absence of
national guidelines. This study highlights the need for a national
register to establish consensuses for the management of these
patients.
http://dx.doi.org/10.1016/j.acvd.2013.06.041
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Background.— In the context of new target therapies, this study
aimed to assess the functional status and long-term outcomes of
patients with Eisenmenger Syndrome reaching adulthood.
Patients and methods.— This is a single-centre retrospective review
of all patients diagnosed with Eisenmenger Syndrome. Demograph-
ics, clinical data, underlying cardiac disease, functional status,
therapeutics and outcomes were collected.
Results.— One hundred and ﬁfty-nine patients were included (94
females: 59%), aged 27.7± 14.8 years at end-follow up, and 60 with
Down syndrome (38%). Underlying cardiac disease was: AVSD in 30%,
VSD in 35%, ASD in 9%, PDA in 5%, associated shunts in 5%, com-
plex CHD in 10%, left heart obstruction in 2.5%, pulmonary veins
anomaly in 2.5% and TGA in 1%. CHD was native in 122 cases (77%),
seven had palliation (4%) and 30 complete repair (19%). Pulse oxygen
saturation was 84± 12% (range 44 to 98%), lower in non-operated
or palliated cases (81%) than in repaired cases (92%, P = 0.002).
Patients were in NYHA class I (18%), class II (42%), class III (37%)
or IV (3%), not different with previous repair or not. Target therapy
agents were given in 35% of the cases (one agent in 20%, two asso-
ciated in 13%, intravenous epoprostenol in 1.5%). Death occurred
in 26 patients (16%) at the age of 29.3± 17.8years. Complications
occurred in most of the cases (64%) including: hemorrhages events,
syncopes, thrombo-embolia, cerebral abscess, infective endocardi-
tis, heart failure or arrhythmias. NYHA class did not differ between
patients with or without target therapy. SpO2 was 82% in untreated
cases compared to 86% in treated cases (NS). Survival rates were:
98% at 10-years, 93% at 20-years, 87% at 30-years, 83% at 40-years,
73% at 50-years and 53% at 60-years of follow-up. Survival was
lower in Down patients (P = 0.0023), in males (P = 0.04) and tends
to be higher up to 50-years of age in patients under target therapy
(P = 0.05).
Conclusion.— The survival rate of adult patients with Eisenmenger
Syndrome seems to improve up to 50 years of age with target ther-
apy agents. These results have to be conﬁrmed by larger scale
multicentre studies.
http://dx.doi.org/10.1016/j.acvd.2013.06.042
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Background.— Infective endocarditis (IE) may adversely impact
on long term prognosis of patients with CHD reaching adulthood
(ACHD). The aim of this study was to assess the features and out-
come of IE in ACHD.
Patients and methods.— Design is a single centre retrospective
chart review of IE episodes in patients with CHD and aged > 18y at
diagnosis. Demographics, past cardiac history, clinical and echocar-
diographic, therapeutics data and outcomes were reviewed.
Results.— From 1980 to 2011, 33 patients were included, mean age
29 years at IE (range 18 to 76). Underlying CHDs were: native VSD in
22%, cyanotic CHD in 35%, AVSD in 6%, aortic valve lesion in 22% and
miscellaneous in 10%. CHD was repaired in 19%, palliated in 27% and
non-operated in 54%. Thirty percent had received antibiotics prior
to IE diagnosis. Heart failure occurred in 22% of cases, septic shock
in 11%, neurological complication in 11%, splenomegalia was present
in 46% and fever in 100% of cases. Source of infection was dental
in 35%, cutaneous in 25%, ENT in 5%. The microbial causal agent
was Staphylcoccus in 46% and Streptococcus in 32.5%, unknown in
8%. Echocardiographic vegetations were found in 49% of the cases,
valves perforation or abscesses occurred in 11% and 24%. Embolic
events were frequent (62%). Surgery was performed in 30% of cases,
a median of 21 days after onset of IE (1 day to 5 months). Hospital
stay was 2 weeks to 6 months. Mortality was 11% and two cases
recurred.
Conclusion.— IE severely impacts the prognosis of ACHD, espe-
cially in patients with cyanotic CHD. Embolic events are frequent
complications. Prophylaxis should mainly focus on cutaneous and
dental procedures.
http://dx.doi.org/10.1016/j.acvd.2013.06.043
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Aims.— The objectives of this pilot prospective monocenter cohort
study were to describe Staphylococcus aureus (SA) colonization in
children before cardiac surgery and to compare the incidence of
surgical site infection (SSI) and other nosocomial infections between
preoperative carriers and non-carriers.
Methods.— During 9 months, all children < 1 year undergoing car-
diac surgery had preoperative methicillin-resistant (MRSA) and
methicillin-sensitive SA (MSSA) screening by real-time PCR (genX-
pert System, Cepheid®). The only exclusion criterion was invalid
PCR. All patients were followed regarding SSI and other nosocomial
infections. The primary outcome was the comparison of incidence
of SSI among colonized and non-colonized patients.
Results.— Among the 42 studied patients (mean age 2.7± 3 months,
mean weight 4.4± 1.6 kg, mean CBP time 120± 44min, mean hos-
pital length of stay 19.4± 20.9 days, mean intensive care unit
length of stay 8.2± 4.2 days), overall rates of carriage of SA and
of SSI were respectively 24% (21% with MSSA and 2.4% with MRSA)
and 34.1%. Microorganisms were identiﬁed in 36% of the 11 cases
of SSI (9% of MSSA, 9% of MRSA and 18% of coagulase negative
staphylococci (CNS)). Incidence of SSI was not different between
carriers and non-carriers (30% vs 25% respectively, P = 0.29). Only
one CNS bacteriemia and no pneumonia were documented in the
cohort.
Conclusions.— This pilot highlights that colonization with SA is fre-
quent in our country whereas MRSA prevalence is low. At this stage,
data are insufﬁcient to conclude regarding the relationship between
SA carriage and the risk for developing SSI.
http://dx.doi.org/10.1016/j.acvd.2013.06.044
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Background.— Kawasaki disease (KD) is an acute, self-limiting vas-
culitis of unknown etiology. The incidence of KD is increasing
worldwide. However, there is a lack of data on Kawasaki disease
and its effect on coronary arteries in Algeria and other developing
countries.
Objective.— To describe the pattern of cardiovascular involvement
in Algerian children admitted with Kawasaki disease and to highlight
the practical difﬁculties.
